RET inhibitor for use in treating cancer having a RET alteration

• 收藏
• 分享

专利权人:

Blueprint Medicines Corporation

发明人:

EVANS RAAB, Erica,WOLF, Beni B.

申请号：

AU2019247766

公开号：

AU2019247766A1

申请日:

2019.04.03

申请国别(地区):

AU

年份:

2020

代理人:

摘要：

Disclosed herein is the treatment of a subject afflicted with a cancer having an activating RET alteration by administering an effective amount of a selective RET inhibitor, e.g., Compound 1 or pharmaceutically acceptable salts thereof, including, e.g., administering an amount of 300 mg to 400 mg of the selective RET inhibitor once daily.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/